Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Project Oncology®

Selecting High-Risk Mantle Cell Lymphoma Patients for CAR T-Cell Therapy

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Sponsored by

  • Overview

    When it comes to managing patients with high-risk mantle cell lymphoma, several factors impact their candidacy for CAR T-cell therapy, including time to relapse, TP53 mutation status, age, and even social considerations. Joining Dr. Charles Turck to discuss how we can use these factors to identify patients with high-risk mantle cell lymphoma who would most likely benefit from CAR T-cell therapy is medical oncologist Dr. Tara Graff.

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    When it comes to managing patients with high-risk mantle cell lymphoma, several factors impact their candidacy for CAR T-cell therapy, including time to relapse, TP53 mutation status, age, and even social considerations. Joining Dr. Charles Turck to discuss how we can use these factors to identify patients with high-risk mantle cell lymphoma who would most likely benefit from CAR T-cell therapy is medical oncologist Dr. Tara Graff.

Schedule6 Nov 2024